|
Just as manufacturers have outsourced production and call centers, U.S. big pharma has increasingly shifted its drug trials to developing countries. Writing in the New England Journal of Medicine, Duke University researchers question the science and ethics of this shift, arguing that human volunteers in foreign countries may be unduly influenced by the promise of financial compensation or free medical care to participate in clinical trials. Is it right to conduct such studies outside the U.S. to gain approval for drugs that will be used to treat American patients?
The preceding article is a "sneak peek" from Quality Control, a newsletter from GlobalSpec. To stay up-to-date and informed on industry trends, products, and technologies, subscribe to Quality Control today.
|
Comments rated to be "almost" Good Answers: